ChemGenex submits leukemia drug for FDA review

ChemGenex Pharmaceuticals filed for FDA approval of omacetaxine, a drug candidate for chronic myeloid leukemia. The Australian biotech firm hopes to market the small molecule therapy under the brand Omapro in the first half of next year.

View Full Article in:

Herald Sun (Melbourne, Australia) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ